Tamoxifen and the uterus and endometrium

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.

ESMO open·2026

Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.

ESMO open·2026

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study.

ESMO open·2026

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Overall survival with abemaciclib in early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Monthly or menstrual? A scoping review of catamenial epilepsy and non-menstrual seizure rhythms.

Epilepsia·2026

Pharmacokinetic bioequivalence between (etonogestrel/ethinylestradiol 11.7/2.7 mg) NuvaRing® and ornibel premium® (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026

Diagnostic Accuracy of Transvaginal Ultrasound for Endometriosis Does Not Differ Between Women Undergoing Their First Versus Any Subsequent Surgical Treatment.

The Australian & New Zealand journal of obstetrics & gynaecology·2026

Effect of Endometriosis on Surgical Outcomes of Total Laparoscopic Hysterectomy for Benign Indications: A Propensity Score-Matched Analysis.

Asian journal of endoscopic surgery·2026

Conditions That Limit Outpatient Abortion Care at Clinics in the United States.

Perspectives on sexual and reproductive health·2026

Terminal Filament Bundling Underlies the Development of Ovariole Number Dimorphism Between Queen and Worker Ants.

Evolution & development·2026

Related Experiment Videos

Tamoxifen and the uterus and endometrium

Related Concept Videos

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.

Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study.

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Overall survival with abemaciclib in early breast cancer.

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Monthly or menstrual? A scoping review of catamenial epilepsy and non-menstrual seizure rhythms.

Pharmacokinetic bioequivalence between (etonogestrel/ethinylestradiol 11.7/2.7 mg) NuvaRing® and ornibel premium® (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring.

Diagnostic Accuracy of Transvaginal Ultrasound for Endometriosis Does Not Differ Between Women Undergoing Their First Versus Any Subsequent Surgical Treatment.

Effect of Endometriosis on Surgical Outcomes of Total Laparoscopic Hysterectomy for Benign Indications: A Propensity Score-Matched Analysis.

Conditions That Limit Outpatient Abortion Care at Clinics in the United States.

Terminal Filament Bundling Underlies the Development of Ovariole Number Dimorphism Between Queen and Worker Ants.

Related Experiment Videos

Tamoxifen and the uterus and endometrium

Related Concept Videos

Related Articles